Menu
← Oncology Approval Tracker
FDA DECISION ·
Tevimbra + platinum and fluoropyrimidine
tislelizumab-jsgr with platinum and fluoropyrimidine chemotherapy · BeiGene
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First-line combination treatment for adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 at a score of at least 1.
LAMPGEN ANALYSIS
Why it matters
This action added a biomarker-defined gastric and junctional indication to the checkpoint inhibitor’s earlier esophageal label.
What research teams should watch
Keep the applicable PD-L1 scoring method and the HER2 result with the first-line treatment record.
PRIMARY RECORDS